RELMADA THERAPEUTICS INC (RLMD:NASDAQ)
$5.31 -0.04 (-0.7477%)
Analysed RELMADA THERAPEUTICS INC (RLMD:NASDAQ) News Sources
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
12-05-2026
yahoo.com
Relmada Therapeutics Q1 Earnings Call Highlights
13-05-2026
marketbeat.com
Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...
13-05-2026
yahoo.com
Relmada Therapeutics, Inc. Q1 2026 Earnings Call Summary
13-05-2026
moby.co
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
28-05-2026
yahoo.com
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
11-06-2026
yahoo.com
Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now
19-06-2026
yahoo.com
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
29-06-2026
yahoo.com
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
16-07-2026
yahoo.com
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
28-07-2026
yahoo.com
What is the current price of RELMADA THERAPEUTICS INC (RLMD:NASDAQ)?
The current price of RELMADA THERAPEUTICS INC (RLMD:NASDAQ) is $5.31.
RELMADA THERAPEUTICS INC (RLMD:NASDAQ) absolute price change since previous trading day?
The absolute price change of RELMADA THERAPEUTICS INC (RLMD:NASDAQ) since the previous trading day is $-0.04.
RELMADA THERAPEUTICS INC (RLMD:NASDAQ) percentage price change since previous trading day?
The percentage price change of RELMADA THERAPEUTICS INC (RLMD:NASDAQ) since the previous trading day is -0.7477%.
What is the most recent average sentiment score for RELMADA THERAPEUTICS INC (RLMD:NASDAQ)?
The most recent average sentiment score for RELMADA THERAPEUTICS INC (RLMD:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for RELMADA THERAPEUTICS INC (RLMD:NASDAQ)?
The most recent sentiment for RELMADA THERAPEUTICS INC (RLMD:NASDAQ) is .
SEC-8K** Filing Available For RELMADA THERAPEUTICS INC (RLMD:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.